国际肿瘤学杂志

国际肿瘤学杂志 ›› 2017, Vol. 44 ›› Issue (12): 886-891.doi: 10.3760/cma.j.issn.1673-422X.2017.12.002

• 论著 • 上一篇    下一篇

长非编码RNA RP11-629B11.4在三阴性乳腺癌中的表达及意义

潘海霞,梁良,任刚,白义凤   

  1. 610072 成都，四川省医学科学院 四川省人民医院肿瘤中心
  • 出版日期:2017-12-08 发布日期:2017-12-01
  • 通讯作者: 白义凤，Email: 15756285949@163.com E-mail:15756285949@163.com
  • 基金资助:
    国家自然科学基金（81301910）

Expression and significance of long non-coding RNA RP11629B11.4 in triple negative breast cancer patients

Pan Haixia, Liang Liang, Ren Gang, Bai Yifeng   

  1. Department of Oncology, Sichuan Academy of Medical Sciences & Sichuan Provincial People′s Hospital, Chengdu 610072, China
  • Online:2017-12-08 Published:2017-12-01
  • Contact: Bai Yifeng, Email: 15756285949@163.com E-mail:15756285949@163.com
  • Supported by:
    National Natural Science Foundation of China (81301910)

PDF

613

摘要： 目的探讨长非编码RNA（lncRNA） RP11-629B11.4在三阴性乳腺癌（TNBC）中的表达及临床意义。方法通过实时荧光定量聚合酶链反应（qRT-PCR）检测TNBC患者（n=45）及非三阴性乳腺癌（N-TNBC）患者(n=89)组织标本中RP11-629B11.4的表达，分析RP11-629B11.4表达与TNBC患者预后的相关性。结果lncRNA RP11-629B11.4在TNBC组织中的平均表达水平为7.805±0.538，明显高于N-TNBC组织的1.637±0.409，差异有统计学意义（t=21.460，P＜0.001）。RP11-629B11.4的表达与TNBC患者组织学分级（χ2=7.540，P=0.040）、临床分期（χ2=9.858，P=0.007）、淋巴结转移（χ2=4.388，P=0.036）及Ki-67的表达（χ2=7.872，P=0.005）相关；在NTNBC组中RP11629B11.4的表达与患者临床病理特征均无明显相关性（均P＞0.050）。高表达lncRNA RP11-629B11.4的TNBC患者中位无进展生存时间为(15.90±2.76)个月，较低表达患者的(26.62±3.80)个月明显缩短，差异具有统计学意义（χ2=49.750，P＜0.001）。低表达lncRNA RP11-629B11.4的患者中位总生存时间为(38.84±3.55)个月，较高表达患者的(24.69±3.50)个月明显延长，差异具有统计学意义（χ2=50.730，P＜0.001）。Cox多因素回归模型分析提示，淋巴结转移（HR=1.980，P=0.019）、lncRNA RP11-629B11.4的表达（HR=4.030，P＜0.001）及临床分期（HR=2.670，P=0.008）是影响TNBC患者预后的因素。结论lncRNA RP11-629B11.4在TNBC中高表达，其参与调节TNBC的发生发展，可作为评估TNBC临床预后的潜在靶基因。

关键词: 乳腺肿瘤, 预后, 长非编码RAN RP11-629B11.4

Abstract: ObjectiveTo investigate the expression and clinical significance of long non-coding RNA (lncRNA) RP11629B11.4 in triple negative breast cancer (TNBC) patients. MethodsThe expression of lncRNA RP11629B11.4 was detected by real-time fluorescent quantitative polymerase chain reaction (qRT-PCR) in TNBC tissues （n=45） and non triple negative breast cancer (N-TNBC， n=89) to analyze the relationship between the expression of lncRNA RP11-629B11.4 and the prognosis of patients. ResultsThe expression of lncRNA RP11-629B11.4 in TNBC tissues was 7.805±0.538, significantly higher than that in N-TNBC tissues (1.637±0.409, t=21.460, P＜0.001). The expression of lncRNA RP11-629B11.4 in the TNBC patients was related with histological grade (χ2=7.540, P=0.040), clinical stage (χ2=9.858, P=0.007), lymph node metastasis (χ2=4.388, P=0.036) and Ki-67 expression (χ2=7.872, P=0.005). In the N-TNBC group, there was no significant correlation between the expression of lncRNA RP11-629B11.4 and clinicopathological characteristics (all P＞0.050). The progression free survival time of TNBC patients with higher expression of lncRNA RP11-629B11.4 was (15.90±2.76) months, shorter than that of patients with lower expression (26.62±3.80) months, with a statistically significant difference (χ2=49.750, P＜0.001). The overall survival time of TNBC patients with lower expression of lncRNA RP11-629B11.4 was (38.84±3.55) months, significantly longer than that of patients with higher expression ［(24.69±3.50) months］, with a statistically significant difference (χ2=50.730, P＜0.001). Cox regression model analysis showed that lymph node metastasis (HR=1.980, P=0.019), the expression of lncRNA RP11-629B11.4 (HR=4.030, P＜0.001)clinical stage (HR=2.670, P=0.008) and were independent prognostic factors in patients with TNBC. ConclusionThe lncRNA RP11629B11.4 is over-expressed in TNBC. lncRNA RP11-629B11.4 may be involved in the regulation of TNBC, and it may be used as a potential target for evaluating the prognosis of TNBC.

Key words: Breast neoplasms, Prognosis, Long non-coding RNA RP11-629B11.4